# Portal Hypertension

Use portal-pressure thresholds and noninvasive risk stratification to identify clinically significant portal hypertension, prevent first decompensation, and select endoscopic or shunt-based therapy for bleeding and refractory ascites.

**Clinical question:** How should physicians stratify, prevent, and treat clinically significant portal hypertension and its major complications?

Updated: 2026-08-24T16:28:16.635346+00:00

## What matters in practice
- An HVPG of at least 10 mmHg defines clinically significant portal hypertension (CSPH), the pressure range associated with varices and decompensation. [6][9][14]
- In compensated advanced chronic liver disease, liver stiffness measurement below 15 kPa plus platelets above 150 × 10^9/L rules out CSPH; liver stiffness measurement of at least 25 kPa confirms CSPH. [16]
- Use a nonselective beta-blocker to prevent decompensation in CSPH; reserve endoscopic variceal ligation for compensated patients with high-risk esophageal varices who cannot take a nonselective beta-blocker. [12]
- Consider TIPS for refractory ascites and secondary prophylaxis of esophageal variceal hemorrhage, while balancing benefit against hepatic encephalopathy and cardiopulmonary risk. [11][23][24]

## Identify the portal-pressure phenotype that changes management

Separate compensated risk stratification from active portal-hypertensive complications.

Hepatic venous pressure gradient (HVPG) is the difference between wedged and free hepatic venous pressures and remains the reference standard for portal-pressure measurement. Portal hypertension is conventionally defined by HVPG at least 5 mmHg; CSPH is defined by HVPG at least 10 mmHg and is associated with development of varices and clinical decompensation. [6][14]

Use HVPG selectively when a direct hemodynamic measurement will resolve an important management question. Interpret a normal or low HVPG cautiously when presinusoidal disease is suspected, because wedged hepatic venous pressure measurement does not detect presinusoidal portal hypertension, including portal-vein obstruction. [14]

Treat ascites, variceal hemorrhage, and hepatic encephalopathy as decompensating events rather than as isolated findings; compensated versus decompensated status is a major prognostic and therapeutic branch. [15] Acute gastrointestinal bleeding requires immediate hemodynamic assessment and source-directed endoscopic management rather than outpatient noninvasive risk stratification.

*Portal-pressure assessment thresholds and their clinical interpretation. [6][14][16]*

| Finding | Interpretation | Next clinical use |
| --- | --- | --- |
| HVPG ≥5 mmHg | Portal hypertension. [6][14] | Establishes hemodynamic portal hypertension when directly measured. [6][14] |
| HVPG ≥10 mmHg | CSPH; associated with varices and decompensation. [6][9][14] | Initiate prevention strategy for decompensation when clinically appropriate. [12] |
| LSM <15 kPa and platelets >150 × 10^9/L | Rules out CSPH in the Baveno VII noninvasive framework. [16] | Avoid labeling the patient as having CSPH on the basis of compensated advanced chronic liver disease alone. [16] |
| LSM ≥25 kPa | Confirms CSPH in the Baveno VII noninvasive framework. [16] | Assess candidacy for nonselective beta-blocker therapy and portal-hypertension surveillance. [12][16] |

## Use elastography and platelets to triage compensated advanced chronic liver disease

Apply noninvasive criteria before reflexively ordering endoscopy or invasive pressure measurement.

Obtain vibration-controlled transient elastography liver stiffness measurement (LSM) and platelet count in compensated advanced chronic liver disease. LSM below 15 kPa with platelets above 150 × 10^9/L rules out CSPH, whereas LSM at least 25 kPa confirms CSPH. [16] Patients between these boundaries require individualized risk assessment rather than binary classification from either test alone.

LSM reflects cumulative stiffness from fibrosis and portal hypertension in cirrhosis and correlates with HVPG; however, values may vary materially between transient-elastography systems and agreement decreases with higher body mass index. Follow patients with the same validated platform when serial LSM will influence management. [7][15]

Spleen stiffness may add information when LSM is indeterminate. A spleen stiffness threshold of at least 21 kPa has been used to screen for CSPH, but this threshold should not replace the better-established LSM/platelet rule-out and rule-in criteria. [8][16]
- Do not use HVPG alone to exclude portal hypertension when portal-vein obstruction or another presinusoidal process is plausible. [14]
- If LSM is below 20 kPa and platelets exceed 150 × 10^9/L, prior Baveno criteria did not recommend screening endoscopy; reconcile this with current CSPH-directed management and the individual indication for variceal assessment. [15][16]

## Select nonselective beta-blockade or ligation for high-risk varices

The preventive goal in CSPH is prevention of first decompensation, not only prevention of first bleeding.

For compensated cirrhosis with CSPH, use a nonselective beta-blocker (NSBB) to prevent decompensation. Current consensus cited in the clinical literature places NSBBs first-line for this objective. [12] Carvedilol, propranolol, and nadolol reduce portal pressure, but agent selection must account for bradycardia, hypotension, fatigue, respiratory adverse effects, and the potential to worsen refractory ascites, hepatorenal syndrome, or hepatic encephalopathy. [23]

For a compensated patient with high-risk esophageal varices who has a contraindication to or intolerance of NSBB therapy, perform endoscopic variceal ligation (EVL). EVL is an alternative in this setting rather than a routine add-on to tolerated NSBB therapy for primary prevention. [12]

Reassess the risk-benefit balance of NSBB therapy when circulatory intolerance, refractory ascites, hepatorenal syndrome, or recurrent encephalopathy develops. The relevant tradeoff is portal-pressure reduction versus adverse cardiovascular effects and potential deterioration in vulnerable decompensated patients. [23]
- Use NSBB therapy first for compensated CSPH when tolerated. [12]
- Use EVL for high-risk esophageal varices when NSBB therapy is contraindicated or not tolerated. [12]
- Monitor for bradycardia, hypotension, respiratory symptoms, fatigue, and clinical worsening of ascites, hepatorenal syndrome, or encephalopathy after NSBB initiation or adjustment. [23]

## Escalate refractory ascites and recurrent variceal bleeding to TIPS assessment

TIPS offers portal decompression when medical and endoscopic approaches no longer provide adequate control.

For refractory ascites, large-volume paracentesis with human albumin is a first-line strategy cited by Baveno guidance; some patients require procedures every 2 weeks, while others require intervals of 4 to 6 weeks. Consider TIPS as an elective alternative or escalation strategy, recognizing that some patients will still require paracentesis after TIPS. [11]

TIPS is a minimally invasive radiologic portosystemic shunt that directly decompresses portal pressure. Established major indications include treatment of refractory ascites and secondary prophylaxis of esophageal variceal hemorrhage; additional uses include selected early treatment of esophageal variceal hemorrhage, Budd-Chiari syndrome, ectopic varices, and portal-vein thrombosis. [24]

Before TIPS referral, evaluate whether expected decompression benefit outweighs the risk of hepatic encephalopathy and adverse outcomes in patients with cardiopulmonary or hepatic vulnerability. TIPS reduces variceal rebleeding and can control refractory ascites, but encephalopathy is a key tradeoff; NSBBs instead carry hemodynamic and respiratory tolerability constraints. [23][24]

*Portal-decompression options for selected complications. [11][23][24]*

| Clinical problem | Preferred escalation | Principal tradeoff |
| --- | --- | --- |
| Refractory ascites | Large-volume paracentesis plus human albumin; consider elective TIPS. [11][24] | TIPS may improve ascites control but carries hepatic encephalopathy risk. [23] |
| Recurrent esophageal variceal hemorrhage | TIPS for secondary prophylaxis in appropriate candidates. [24] | Balance portal decompression against encephalopathy and patient-specific contraindications. [23][24] |
| Varices inaccessible to endoscopic therapy | Consider portal decompression with TIPS. [24] | Requires procedural candidacy assessment and post-shunt monitoring. [24] |

## Recognize noncirrhotic portal-vein thrombosis as a recurrent-thrombosis phenotype

Do not apply cirrhosis-based assumptions without confirming the underlying vascular disorder.

In noncirrhotic portal-vein thrombosis, long-term complications include gastrointestinal bleeding related to portal hypertension and recurrent thrombosis. [2] Confirm the vascular anatomy and distinguish this phenotype from cirrhotic portal hypertension because HVPG may not detect presinusoidal portal hypertension due to portal-vein obstruction. [14]

Rivaroxaban prophylaxis has been studied to reduce venous thromboembolism and portal-hypertension-related bleeding outcomes in noncirrhotic portal-vein thrombosis. [2][3] Treatment selection should incorporate the competing risks of recurrent thrombosis and portal-hypertensive gastrointestinal bleeding rather than extrapolating directly from cirrhosis algorithms. [2]

## References
1. Supplementary appendix — www.thelancet.com — https://www.thelancet.com/cms/10.1016/S0140-6736(18)31875-0/attachment/a3a3c80c-fc15-4df8-8022-6d2730112473/mmc1.pdf
2. Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis — evidence.nejm.org — https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200104
3. Rivaroxaban Prophylaxis in Noncirrhotic Portal Vein ... — evidence.nejm.org — https://evidence.nejm.org/doi/pdf/10.1056/EVIDoa2200104
4. Esophageal Varices: Development Secondary to Primary ... — jamanetwork.com — https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/583190
5. The Evolution of Portal Hypertension Surgery — jamanetwork.com — https://jamanetwork.com/journals/jamasurgery/fullarticle/390775
6. Noninvasive Assessment of Portal Hypertension in Chronic Liver Disease | Gastroenterology and Hepatology | Clinical Sciences | Health sciences | Topics | Nature Index — www.nature.com — https://www.nature.com/nature-index/topics/l4/noninvasive-assessment-of-portal-hypertension-in-chronic-liver-disease
7. Comparison of two transient elastography (TE) systems for measuring liver stiffness in clinical practice | Scientific Reports — www.nature.com — https://www.nature.com/articles/s41598-025-06151-1
8. Clinically significant portal hypertension assessed by ... — www.nature.com — https://www.nature.com/articles/s41598-025-23635-2
9. The impact of esophagogastric varices on the prognosis ... — www.nature.com — https://www.nature.com/articles/srep42577
10. Comparison with the Portal Hypertension of Cirrhosis and ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-66-1-41
11. Cirrhosis in over 16s: assessment and management (update) — www.nice.org.uk — https://www.nice.org.uk/guidance/ng50/update/ng50-update-1/documents/evidence-review-3
12. Study Details | NCT06594783 | Carvedilol Plus EVL or Not for the Primary Prevention of Esophageal Variceal Bleeding in Carvedilol Non-responders | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT06594783
13. 套扎术对比空白对照用于肝硬化和食管静脉曲张的成人上 ... — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012673.pub2/full/zh_HANS
14. Clinical Study of the BreathID MCS System to train the algorithm ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/78/NCT02143778/Prot_SAP_000.pdf
15. Gawrieh et al. August 5, 2021 - 1 - Non-invasive Evaluation of ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/97/NCT04576897/Prot_000.pdf
16. Assessing the safety of discontinuing non-selective beta- ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/73/NCT06549673/Prot_SAP_000.pdf
17. Study Details | NCT06523608 | Prediction of Decompensation and HCC Development in Advanced Chronic Liver Disease | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT06523608
18. Study Details | NCT04975477 | CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102) | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT04975477
19. Abdominal ultrasound and alpha‐fetoprotein for the ... — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013346/references
20. Study Details | NCT03267615 | VICIS - Vienna Cirrhosis Study | ClinicalTrials.gov — clinicaltrials.gov — https://clinicaltrials.gov/study/NCT03267615
21. Band ligation versus beta‐blockers for primary prophylaxis ... — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010546.pub2/full
22. Platelet count, spleen length, and ... — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008759.pub2/full
23. Transjugular intrahepatic portosystemic shunt and non-selective beta-blockers act as friends or foe in decompensated cirrhosis: A comparative review - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12019065
24. Transjugular Intrahepatic Portosystemic Shunt: Indications, Contraindications, and Patient Work-Up - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC4139433

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.